每经记者｜蔡鼎 每经编辑｜张海妮 贵州烟标龙头永吉股份（603058.SH，股价9.56元，市值40.14亿元）10月9日晚间公告，公司当日召开董事 会和监事会会议，审议通过了相关议案，同意公司终止2025年度向特定对象发行A股股票事项。 永吉股份称："考虑目前资本市场环境的变化，以及结合公司实际情况、发展规划等诸多因素，经审慎分 析并与相关各方充分沟通及论证后，公司决定终止2025年度向特定对象发行A股股票事项。" 《每日经济新闻》记者注意到，这距离永吉股份今年3月12日召开董事会和监事会会议审议通过上述定增 预案已过去半年多。此外，公司2023年曾谋划8.3亿元的定增事项最终也被主动终止。 定增预案涉及多个项目 永吉股份在公告中称，公司目前各项生产经营活动均正常进行，终止本次向特定对象发行股票事项不会对 公司正常经营与稳定发展造成重大不利影响，不存在损害公司及全体股东特别是中小股东利益的情形。 根据公司今年3月份披露的定增预案，本次定增募集资金总额约为4.9亿元，扣除发行费用后的募集资金净 额拟用于收购Phytoca Holdings Pty Ltd（以下简称Phytoca）100%股权、研发设计及打样中 ...

中国经济网北京10月9日讯蜂助手（301382）(301382.SZ)近日发布2025年度向特定对象发行股票预案。 本次发行的募集资金总额不超过98,375.49万元(含本数)，扣除发行费用后的募集资金净额将全部用于以 下项目：云终端算力中心项目、物联网终端智能化升级项目、瘦终端SoC芯片技术研发项目。 | 序号 | 项目名称 | 项目投资总额 | THE MAR 1 事集资金投资额 | | --- | --- | --- | --- | | | 云终端算力中心项目 | 54,841.00 | 54,841.00 | | 2 | 物联网终端智能化升级项目 | 22,103.70 | 22,103.70 | | 3 | 瘦终端 SoC 芯片技术研发项目 | 21,430.80 | 21,430.80 | | | 合计 | 98,375.49 | 98.375.49 | 本次向特定对象发行股票的发行对象为包括公司控股股东、实际控制人罗洪鹏在内不超过35名(含35名) 特定投资者，包括符合中国证监会规定的证券投资基金管理公司、证券公司、信托投资公司、财务公 司、保险机构投资者、合格境外机构投资者以及其他机构投资者、 ...

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]

Core Viewpoint - The company, Cambrian, has announced a private placement of 3,334,946 shares at a price of RMB 1,195.02 per share, raising a total of RMB 3.985 billion, which will be used for chip and software platform projects related to large models and to supplement working capital [1][4]. Summary by Sections Issuance Details - The total number of shares issued is 3,334,946, with a total fundraising amount of RMB 3.985 billion after deducting issuance costs of RMB 32.1713 million [1]. - The final list of 13 investors includes major fund management companies such as GF Fund Management, UBS AG, and Xinhua Asset Management [1][3]. Pricing Information - The issuance price represents a premium of 10.51% over the base price, which is set at 80% of the average trading price over the previous 20 trading days, calculated to be no less than RMB 1,081.32 per share [4]. - The final issuance price of RMB 1,195.02 per share is approximately 90% of the closing price of RMB 1,325 per share on the day of the announcement [4]. Allocation to Investors - The allocation of shares to the investors varies, with GF Fund Management receiving the largest share of 1,010,861 shares, valued at approximately RMB 1.208 billion, and a lock-up period of 6 months [3]. - Other notable allocations include UBS AG with 364,010 shares and Xinhua Asset Management with 351,458 shares, both also subject to a 6-month lock-up period [3].

Core Viewpoint - The company is facing significant financial challenges despite being in a high-growth industry, leading to shareholder concerns about its future and the implications of recent capital activities [1][2][3] Group 1: Company Financial Performance - The company has reported negative net profits for three consecutive years from 2022 to 2024, with losses of 58.56 million, 131 million, and 102 million respectively [1] - In the first half of 2025, the company achieved a revenue of 326 million, a year-on-year increase of 4.09%, but still reported a net loss of 58.67 million, a decrease of 44.52% compared to the previous year [1] - The company's debt-to-asset ratio has increased from 50.24% in 2022 to 66.87% by mid-2025, indicating a concerning level of financial leverage within the industry [1] Group 2: Capital Raising Activities - In August 2025, the company announced a plan to raise up to 159 million by issuing shares to its controlling family, with a subscription price set at 20.11 per share, representing a discount of approximately 23.8% compared to the pre-announcement closing price of 26.38 [2] - The purpose of the capital increase is stated to be optimizing the capital structure and reducing financial risk, with the controlling family fully subscribing to the offering [2] Group 3: Market Reactions and Shareholder Concerns - Concurrently, a significant shareholder, Xinda Securities, announced a plan to reduce its holdings, raising questions about the timing and motivations behind the capital increase and share reduction [3] - The disparity between the capital increase price and the recent market price has led to speculation about potential manipulation, with concerns that the controlling family is benefiting at the expense of other shareholders [3] - The situation has left nearly 10,000 small shareholders questioning whether the company is a misunderstood growth opportunity or merely a pawn in a larger financial game [3]

有意思的是，在公司定增募资的同时，原始股东却悄然减持套现。这种"一边定增、一边减持"的操作引 发市场质疑。 博汇股份的资本运作采用了一个"三步走"策略。根据公告，这场控制权变更交易包含协议转让、定增募 资和表决权让渡三个环节。 2025年4月30日，第一阶段的协议转让已完成过户，原鑫曦望合伙以2.63亿元受让文魁集团持有的 13.06%股份。按此交易计算，每股转让价格约为8.20元。 第二阶段定增方案的最大疑点在于发行价格的确定。根据公告，定增发行价定为5.66元/股，而截至 2025年9月底，博汇股份的股价维持在14元左右。这意味着未来的新主原鑫曦望认购价格不到市价的一 半。 一边是国资入场接手控股权，一边是原始股东大幅减持，博汇股份的资本棋局背后藏着怎样的玄机？ 文魁集团以8.2元 / 股的高价减持，而原鑫曦望以 5.66 元 / 股的低价认购新股，两者价差达 2.54 元 / 股。尽管定增价格符合 "不低于定价基准日前 20 个交易日均价 80%" 的监管要求，但市场质疑这一价差 可能不太公允。 2025年9月，博汇股份发布公告，将定增募资方案从不超过4.17亿元大幅调减至不超过2.35亿元，缩水幅 度 ...

多家公司公告重大资产重组事项，富临精工、国林科技正在筹划重大资产重组，今日（9月30日）早盘 双双"20cm"涨停。 富临精工公告称，公司及宁德时代拟共同对公司子公司江西升华增资扩股，本次交易完成后，宁德时代 持有江西升华的股权比例为51%，富临精工持有股权比例为47.4096%。本次交易预计构成重大资产重 组。 国林科技披露筹划重大资产重组的提示性公告，公司正在筹划以现金方式购买新疆凯涟捷石化有限公司 部分股东持有的目标公司91.07%的股权，本次交易资金来源拟运用自有资金并结合银行并购贷款等方 式筹集资金。本次交易前，公司未持有目标公司的股份，交易完成后，目标公司将成为公司的控股子公 司。 新股提示：两只新股今日上市 N云汉开盘价120元/股，上涨344.44%。公司是一家电子元器件分销与产业互联网融合发展的创新型高 新技术企业，重点聚焦电子制造产业中小批量电子元器件研发、生产、采购需求，通过有效运用数字技 术和互联网技术，基于自建自营的云汉芯城B2B线上商城，主要为电子制造产业提供高效、专业的电子 元器件供应链一站式服务，并延伸至产品技术方案设计、PCBA生产制造服务、电子工程师技术支持等 在内的多个领 ...

中国经济网北京9月30日讯南京证券（601990）(601990.SH)昨日晚间发布公告称，公司于2025年9月29 日收到上海证券交易所出具的《关于南京证券股份有限公司向特定对象发行股票的交易所审核意见》， 认为公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。 南京证券称，公司本次向特定对象发行股票事项尚需经中国证监会同意注册后方可实施，最终能否获得 中国证监会同意注册的决定及时间尚存在不确定性。公司将根据进展情况及时履行信息披露义务。 南京证券6月27日发布的《向特定对象发行A股股票募集说明书(修订稿)》显示，公司本次向特定对象发 行A股股票募集资金总额不超过50.00亿元(含本数)，扣除发行费用后拟全部用于补充公司资本金，具体 拟用于以下方面：用于投资银行业务，提升赋能和服务实体经济能力；用于财富管理业务，完善财富管 理服务和产品体系，增强财富管理综合服务能力；用于购买国债、地方政府债、企业债等证券，助力社 会经济增长，服务实体经济发展；用于资产管理业务，提升资产管理业务主动管理能力，满足客户理财 投资需求；增加对另类子公司和私募子公司的投入，用于股权投资、科创板和创业板跟投；用于信息技 ...

上市仅10个月即启动5.28亿元定增，与此同时股东密集减持套现，富特科技的资本运作引发市场质疑。 2025年7月24日，富特科技抛出"闪电定增"计划——拟向特定对象发行不超过4662.61万股股份，募资5.28亿元用于产能扩张和研发投入。值得注意的是，此次融资距离其2024年9月上市仅10 截至2025年6月30日，公司前次IPO募资3.89亿元中，新能源汽车核心零部件智能化生产制造项目的实际投资金额比募集后承诺投资金额少592.28万元，该项目尚处于建设过程中。 令人感到不解的是，富特科技在发布定增方案后不久，多名股东拟减持套现。 9月11日，富特科技公告称，股东长江蔚来计划在2025年10月13日至2026年1月12日期间，通过大宗交易或竞价交易方式减持不超过466.26万股，占总股本的3%，减持原因为自身资金需求， 长高电新于9月16日审议通过了《关于择机减持参股上市公司富特科技部分股票的议案》，公司拟以集中竞价交易和大宗交易方式择机减持公司所持有的富特科技股票3，465，000股，占富特科 这两大股东的减持计划时间高度重叠，且都在富特科技公布定增方案后不久，这种密集减持行为可能对公司股价形成较大压力。 ...

2025年上半年，富特科技实现营业收入14.74亿元，同比增长高达122.64%；实现那归母净利润仅为 6694.51万元，同比增长率远低于营收增速，仅为15.15%。2024 年公司实现营业收入19.34亿元，同比增 长5.38%；但全年公司扣非归母净利润净利润出现19.3%的下滑。 上市仅10个月即启动5.28亿元定增，与此同时股东密集减持套现，富特科技的资本运作引发市场质疑。 2025年7月24日，富特科技抛出"闪电定增"计划——拟向特定对象发行不超过4662.61万股股份，募资 5.28亿元用于产能扩张和研发投入。值得注意的是，此次融资距离其2024年9月上市仅10个月，远超"前 次融资满18个月"的常规间隔。 截至2025年6月30日，公司前次IPO募资3.89亿元中，新能源汽车核心零部件智能化生产制造项目的实际 投资金额比募集后承诺投资金额少592.28万元，该项目尚处于建设过程中。 令人感到不解的是，富特科技在发布定增方案后不久，多名股东拟减持套现。 9月11日，富特科技公告称，股东长江蔚来计划在2025年10月13日至2026年1月12日期间，通过大宗交易 或竞价交易方式减持不超过466.26 ...